The Managing of Gaucher Disease Type 1(GD)
Loading...
Date
2018-04-14
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
faculty of Basic Medical Science - Libyan International Medical University
Abstract
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder that results from loss of
function of acid β- glucosidase and there are about 200 mutations in acid- β -glucosidase (GlcCerase)
have been described, to manage this disease there are two treatments are available the enzyme
replacement therapy (ERT) and the substrate reduction therapy.
There are nearly about 3 types of this disease
Description
Gaucher disease, the most common lysosomal storage disorder, is caused by the defective activity of the
lysosomal enzyme, acid-β-glucosidase (GlcCerase), leading to accumulation of glucosylceramide
(GlcCer), particularly in cells of the macrophage lineage. Nearly 200 mutations in GlcCerase have been
described, but for the most part, genotype-phenotype correlations are weak, and little is known about the
down-stream biochemical changes that occur upon GlcCer accumulation that result in cell and tissue
dysfunction. In contrast, the clinical course of Gaucher disease has been well described, and at least one
treatment is available, namely enzyme replacement therapy. One other treatment, substrate reduction
therapy
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwised noted, this item's license is described as Attribution 3.0 United States